|Research Article:||Antiviral Dosing Modification for Coronavirus Disease 2019–Infected Patients Receiving Extracorporeal Therapy|
|Author:||Weerachai Chaijamorn, Dhakrit Rungkitwattanakul, Nantana Nuchtavorn, Taniya Charoensareerat, Sutthiporn Pattharachayakul, Wiriyaporn Sirikun, Nattachai Srisawat|
|Department/Faculty||Faculty of Pharmacy, Siam University, Bangkok 10160|
|Published:||Critical Care Explorations: October 01, 2020 – Volume 2 – Issue 10 – p e0242
Weerachai Chaijamorn, Dhakrit Rungkitwattanakul, Nantana Nuchtavorn, Taniya Charoensareerat, Sutthiporn Pattharachayakul, Wiriyaporn Sirikun, Nattachai Srisawat. (2020). Antiviral dosing modification for Coronavirus Disease 2019 – Infected patients receiving extracorporeal therapy. Critical Care Explorations. 2(10), e0242.
Previous literature regarding coronavirus disease 2019 outlined a presence of organ dysfunction including acute respiratory distress syndrome and acute kidney injury that are linked to mortality. Several patients require extracorporeal therapy. This review aims to gather available published resources including physicochemical and pharmacokinetic properties and suggests antiviral drug dosing adaptation for coronavirus disease 2019–infected critically ill patients receiving extracorporeal therapy. A literature search was performed using PubMed, clinical trial registries, and bibliographic review of textbooks and review articles. Unfortunately, no standard of pharmacologic management and recommendations of drug dosing for coronavirus disease 2019 infection for critically ill patients receiving extracorporeal therapy exist due to the limited data on pharmacokinetics and clinical studies. All available extracted data were analyzed to suggest the appropriate drug dosing adjustment. Antiviral drug dosing adjustments for critically ill patients receiving extracorporeal membrane oxygenation and continuous renal replacement therapy are presented in this review. Considering pathophysiologic changes, drug properties, and extracorporeal modalities, applying our suggestion is recommended.
Key Words: antivirals, continuous renal replacement therapy, coronavirus disease 2019, extracorporeal membrane oxygenation, extracorporeal therapy.
Antiviral Dosing Modification for Coronavirus Disease 2019–Infected Patients Receiving Extracorporeal Therapy
Faculty of Pharmacy, Siam University, Bangkok, Thailand
- Thromboprophylaxis in Multiple Myeloma Patients Receiving Immunomodulatory Drugs
- The Perspective of Stakeholders towards the Problems and Solutions of Health Products Available Through Social Commerce in Thailand
- Prognostic Value of Serum Procalcitonin level for the Diagnosis of Bacterial Infections in Critically-ill Patients
- Formulation and in-vitro evaluation of fast dissolving tablets using superdisintegrant blend with effervescent materia
- Doripenem dosing regimens in Asian critically ill patients with continuous real replacement therapy
- Doripenem dosing in Asian critically ill patients with continuous renal replacement therapy
- Design and characterisation of electrospun shellac-polyvinylpyrrolidone blended micro/nanofibres loaded with monolaurin for application in wound healing